Arthrogen is seeking a highly skilled and motivated molecular biologist to join our team. He/she will be involved in the execution of current and new projects and external collaborations, focusing on the generation of new AAV-based vectors targeting inflammatory disease. The aim of these projects is to develop new product candidates for clinical testing. In addition, the research should generate new intellectual property to protect Arthrogen’s future products. The senior scientist will be responsible for design and construction of the vectors, including biochemical and in vitro characterization. He/she will closely cooperate with Arthrogen’s nonclinical development team in designing and executing proof of concept studies using the vectors. The senior scientist will have a unique opportunity to conduct interdisciplinary collaborative research at Arthrogen. He/she is expected to work independently with supervision, identify challenges and demonstrate motivation in pursuing scientific answers through thorough experimental planning and critical analysis of data. EDUCATION AND EXPERIENCE REQUIREMENTS:• University degree and a PhD in Molecular Biology, Biochemistry, Virology or related and 2-5 years’ experience in academia or industry.• Strong track record of scientific publications.• Experience in the design, construction and therapeutic development of rAAV vectors. • Proficiency in molecular biology including hands on experience in complex DNA cloning, sequencing, and optimizing gene expression cassettes for gene therapy vectors.• He/she has excellent communication and documentation skills, is persistent and pro-active. PREFERRED SKILLS:• Scientific knowledge of inflammation.• Experience in supervising technicians.• Experience in GxPs Arthrogen is an Amsterdam based clinical stage biopharmaceutical company, developing local gene therapy for inflammatory diseases. Arthrogen specializes in the development of viral gene therapy vectors, in particular adeno-associated virus (AAV-) based therapeutics. Arthrogen’s lead product, ART-I02, is an AAV2/5 based gene therapy vector expressing human interferon-β for the treatment of rheumatoid arthritis. ART-I02 is currently in clinical development (Phase Ib). Several other product candidates are in the discovery and development phase. Our discovery research programs address new delivery, new target genes and new indications. In these programs, we work together with world leading scientists.